NEW YORK/BOSTON (Reuters) – Teva Pharmaceutical Industries Ltd’s proposed $23 billion (£17.85 billion) drug giveaway to settle thousands of U.S. opioid lawsuits will likely cost the company a fraction of that figure due to how it has valued those medicines, according to a Reuters review of pricing data and industry analysts. When Teva announced the value of the donated medicine – a generic version of opioid addiction treatment Suboxone – it based the figure on the drug’s list price, which does not account for significant discounts routinely provided by the drugmaker. If based on the estimated cost …read more
Source:: Yahoo Finance
